SAVA

Cassava Sciences Inc. (SAVA) | Rumor.io

Cassava Sciences

SAVA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,350

Bullish sentiment (50-day avg)25%

Price to earnings ratio-0.4

Market capitalization36.1M

Earnings per share-2.22

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-91M

Social

What share of all stock conversation is about SAVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% -0.05

Apr 8

SAVA's status is uncertain, with some speculating it may be finished, but the author is unsure what will happen next.
The author is currently analyzing Bitcoin and global markets, as well as macroeconomic developments and news.
The post does not mention Cassava Sciences, Inc. or its stock price, and only mentions SAVA in passing.

Generated by AI

Sentiment

Of the messages about SAVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	82.21% +27.99
Bearish	—	—	—	17.79% -27.99

Bullish· Mar 10

$SAVA is on track to double in value, with a potential 10-cent price increase.
Cassava Sciences' Simufilam data from clinical trials has huge potential to disrupt the Alzheimer's treatment market.
The stock is seeing significant volume follow-through and a nice gapper, indicating a strong price movement.

Bearish· Dec 19

$SAVA has settled a class action suit for $31m, a relatively small amount compared to the funds raised.
The company's clinical trial for simufilam in TSC-related epilepsy has been put on hold, which may impact the stock's performance.
$SAVA's management has been criticized for bonuses paid despite the company's struggles and investors' losses, which may further erode investor confidence.

Generated by AI

Topics

Of the messages about SAVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Controversies	—	100%	66.67%	4.97%
Announcements	—	0%	33.33%	16.06%
Analysts	—	0%	0%	27.61%
Earnings	—	0%	0%	0.04%
Macro	—	0%	0%	26.9%
Technical Analysis	—	0%	0%	24.42%

Earnings· Nov 10

Cassava Sciences, Inc. ($SAVA) has announced its Q3 financial results without a conference call.
The company reported a loss of $0.24 per share, missing the consensus estimate by $0.07.
The Q3 results show an increase in expenses due to phase 3 trial costs, but are considered positive news as the trial is ramping up.

Analysts· Jan 24

HC Wainwright analyst Vernon Bernardino reiterated a Buy rating on Cassava Sciences (SAVA) with a $124 price target, citing solid data and potential to change the trajectory of Alzheimer's disease.
10 analysts analyzed SAVA, with a 76% buy consensus, indicating mild confidence in the stock.
Analysts Soumit Roy from JonesTrading and Vernon Bernardino from HC Wainwright reiterated Buy ratings on SAVA, with price targets of $100 and $124, respectively.

Announcements· Mar 11

Cassava Sciences, Inc. ($SAVA) has announced a name change to Filana Therapeutics, Inc. ($FLNA).
The name change is effective immediately, and the company's ticker symbol will also be updated.
This change is part of the company's efforts to rebrand and reflect its new direction.

Controversies· Feb 19

The U.S. Department of Justice Fraud Section has closed its inquiry into Cassava Sciences regarding allegations of research misconduct.
The investigation was related to simufilam, an Alzheimer's research, and follows the dismissal of a prior indictment in United States v. Wang.
The closure of the investigation removes a significant overhang for the company, but may lead to increased volatility in its stock price.

Technical Analysis· Sep 23

The CEO of Cassava Sciences, Richard Barry, has made a significant purchase of shares, acquiring 237,941 shares at an average price of $2.25 each.
The stock has broken out of a downtrend and has a massive gap above, potentially leading to a run to $25 or more.
The stock has a high short interest, with 13% of the float shorted, which could lead to a short squeeze and further price increases.

Generated by AI

Community

Of the messages about SAVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	92.86%	86.67%	55.73%
Newcomers	100%	7.14%	13.33%	44.27%

Regulars· Feb 18

The regulars are concerned about naked short selling, which they believe is harming the stock price of Cassava Sciences, Inc. (SAVA).
The regulars argue that the company's research and development of life-improving drugs is being unfairly targeted by short sellers who do not want to see these treatments become available.
The regulars believe that the negative impact of short selling on SAVA's stock price is unjust and potentially harming the company's ability to bring these treatments to market.

Newcomers· Mar 10

The company Cassava Sciences, Inc. (now known as Filana Therapeutics, Inc.) has officially changed its name and ticker symbol from $SAVA to $FLNA.
Newcomers to the $SAVA (now $FLNA) stock are looking at the company's chart and seeking potential opportunities for growth.
Cassava Sciences, Inc. (now Filana Therapeutics, Inc.) is making progress in Alzheimer's treatments with promising data from clinical trials, particularly with Simufilam, and is awaiting FDA updates and next-stage trial results.

Generated by AI

Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigatorsOngoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a bio

7d agoYahoo Finance

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on...

1mo agoBarchart.com

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology...

2mo agomarkets.businessinsider.com

Also Discussed

Investors talking about SAVA also mention

#	Name	Attention
1	Annovis Bio, Inc.ANVS	0%0
2	SAVAW - Cassava Sciences, Inc. Warrant	——
3	Anavex Life Sciences CorpAVXL	0.01%+0
4	Biogen IncBIIB	0%-0.01
5	CYTH - Cyclo Therapeutics, Inc.	——
6	AC Immune SAACIU	0%0
7	Alector Inc.ALEC	0%new
8	SCPH - scPharmaceuticals Inc.	——
9	INmune Bio Inc.INMB	0%0
10	ATHA - Athira Pharma, Inc.	——

Cassava Sciences Inc.

Healthcare
Biotechnology

Cassava Sciences Inc. is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system disorders. Its primary product candidate, simufilam, is an investigational oral small molecule drug currently advancing in preclinical studies for tuberous sclerosis complex (TSC)-related epilepsy, where it has shown reductions in seizure activity in mouse models. The company previously explored simufilam and the diagnostic SavaDx for Alzheimer's disease but discontinued that program following Phase 3 trial results. Cassava Sciences Inc. conducts research emphasizing unmet needs in neurodegenerative and neurological conditions, supported by a team of experienced professionals in neuroscience, clinical development, and regulatory affairs. Headquartered in Austin, Texas since its name change in 2019, and founded in 1998, the company maintains a streamlined operation dedicated to advancing its pipeline through proof-of-concept studies and strategic hires in epilepsy therapeutics.

Website

Location

6801 N. Capital of Texas Highway

Austin, TX, 78731

United States

Social

What share of all stock conversation is about SAVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% -0.05

Apr 8

SAVA's status is uncertain, with some speculating it may be finished, but the author is unsure what will happen next.
The author is currently analyzing Bitcoin and global markets, as well as macroeconomic developments and news.
The post does not mention Cassava Sciences, Inc. or its stock price, and only mentions SAVA in passing.

Generated by AI

Sentiment

Of the messages about SAVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	82.21% +27.99
Bearish	—	—	—	17.79% -27.99

Bullish· Mar 10

$SAVA is on track to double in value, with a potential 10-cent price increase.
Cassava Sciences' Simufilam data from clinical trials has huge potential to disrupt the Alzheimer's treatment market.
The stock is seeing significant volume follow-through and a nice gapper, indicating a strong price movement.

Bearish· Dec 19

$SAVA has settled a class action suit for $31m, a relatively small amount compared to the funds raised.
The company's clinical trial for simufilam in TSC-related epilepsy has been put on hold, which may impact the stock's performance.
$SAVA's management has been criticized for bonuses paid despite the company's struggles and investors' losses, which may further erode investor confidence.

Generated by AI

Topics

Of the messages about SAVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Controversies	—	100%	66.67%	4.97%
Announcements	—	0%	33.33%	16.06%
Analysts	—	0%	0%	27.61%
Earnings	—	0%	0%	0.04%
Macro	—	0%	0%	26.9%
Technical Analysis	—	0%	0%	24.42%

Earnings· Nov 10

Cassava Sciences, Inc. ($SAVA) has announced its Q3 financial results without a conference call.
The company reported a loss of $0.24 per share, missing the consensus estimate by $0.07.
The Q3 results show an increase in expenses due to phase 3 trial costs, but are considered positive news as the trial is ramping up.

Analysts· Jan 24

HC Wainwright analyst Vernon Bernardino reiterated a Buy rating on Cassava Sciences (SAVA) with a $124 price target, citing solid data and potential to change the trajectory of Alzheimer's disease.
10 analysts analyzed SAVA, with a 76% buy consensus, indicating mild confidence in the stock.
Analysts Soumit Roy from JonesTrading and Vernon Bernardino from HC Wainwright reiterated Buy ratings on SAVA, with price targets of $100 and $124, respectively.

Announcements· Mar 11

Cassava Sciences, Inc. ($SAVA) has announced a name change to Filana Therapeutics, Inc. ($FLNA).
The name change is effective immediately, and the company's ticker symbol will also be updated.
This change is part of the company's efforts to rebrand and reflect its new direction.

Controversies· Feb 19

The U.S. Department of Justice Fraud Section has closed its inquiry into Cassava Sciences regarding allegations of research misconduct.
The investigation was related to simufilam, an Alzheimer's research, and follows the dismissal of a prior indictment in United States v. Wang.
The closure of the investigation removes a significant overhang for the company, but may lead to increased volatility in its stock price.

Technical Analysis· Sep 23

The CEO of Cassava Sciences, Richard Barry, has made a significant purchase of shares, acquiring 237,941 shares at an average price of $2.25 each.
The stock has broken out of a downtrend and has a massive gap above, potentially leading to a run to $25 or more.
The stock has a high short interest, with 13% of the float shorted, which could lead to a short squeeze and further price increases.

Generated by AI

Community

Of the messages about SAVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	92.86%	86.67%	55.73%
Newcomers	100%	7.14%	13.33%	44.27%

Regulars· Feb 18

The regulars are concerned about naked short selling, which they believe is harming the stock price of Cassava Sciences, Inc. (SAVA).
The regulars argue that the company's research and development of life-improving drugs is being unfairly targeted by short sellers who do not want to see these treatments become available.
The regulars believe that the negative impact of short selling on SAVA's stock price is unjust and potentially harming the company's ability to bring these treatments to market.

Newcomers· Mar 10

The company Cassava Sciences, Inc. (now known as Filana Therapeutics, Inc.) has officially changed its name and ticker symbol from $SAVA to $FLNA.
Newcomers to the $SAVA (now $FLNA) stock are looking at the company's chart and seeking potential opportunities for growth.
Cassava Sciences, Inc. (now Filana Therapeutics, Inc.) is making progress in Alzheimer's treatments with promising data from clinical trials, particularly with Simufilam, and is awaiting FDA updates and next-stage trial results.

Generated by AI

Cassava Sciences

Social

Apr 8

Bullish· Mar 10

Bearish· Dec 19

Earnings· Nov 10

Analysts· Jan 24

Announcements· Mar 11

Controversies· Feb 19

Technical Analysis· Sep 23

Regulars· Feb 18

Newcomers· Mar 10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

Also Discussed

Cassava Sciences Inc.

Company Information

Location

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

Also Discussed

Social

Apr 8

Bullish· Mar 10

Bearish· Dec 19

Earnings· Nov 10

Analysts· Jan 24

Announcements· Mar 11

Controversies· Feb 19

Technical Analysis· Sep 23

Regulars· Feb 18

Newcomers· Mar 10